This monthly feature will help readers keep current on new drugs, new indications, dosage forms, and safety-related changes in labeling or use. Efforts have been made to ensure the accuracy of this information; however, if there are any questions, please let me know at danial.baker@wsu.edu.
Current FDA-Related Drug Information
The application that was submitted to the FDA used a combination of daclatasvir and asunaprevir for the treatment of hepatitis C virus (HCV); since that time asunaprevir has been withdrawn by BMS. The FDA has requested data on the effectiveness and safety of daclatasvir with other antiviral agents.
Recommended for approval by an FDA advisory panel
Ceftazidime-avibactam (Actavis) Treatment of complicated intra-abdominal infections and complicated urinary tract infections caused by gram-negative pathogens when little or no treatment options are available. The Committee did not recommend its approval for the treatment of hospital-acquired bacterial pneumonia or bacteremia.
Agents scheduled for review by an FDA advisory panel
Desmopressin
Orally disintegrating sublingual tablets for the treatment of nocturia due to nocturnal polyuria in adults who awaken 2 or more times each night to void (meeting date: January 12, 2015) 
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CONTRAINDICATIONS
Xiaflex is contraindicated in the treatment of Peyronie's plaques that involve the penile urethra due to potential risk to this structure and in patients with a history of hypersensitivity to Xiaflex or to collagenase used in any other therapeutic application or application method. WARNINGS AND PRECAUTIONS Tendon Rupture or Other Serious Injury to the Injected Finger/Hand in the Treatment of Dupuytren's Contracture • Information regarding the risk of skin laceration was added. The possible increased risk for 2 concurrent injections over a single injection is described, as well as postmarketing experience with serious skin lacerations requiring skin graft. • Orthostatic hypotension, falls, and syncope have been reported with therapeutic doses of Cymbalta. Syncope and orthostatic hypotension tend to occur within the first week of therapy but can occur at any time during Cymbalta treatment, particularly after dose increases. The risk of falling appears to be related to the degree of orthostatic decrease in blood pressure as well as other factors that may increase the underlying risk of falls. In an analysis of patients from all placebo-controlled trials, patients treated with Cymbalta reported a higher rate of falls compared to patients treated with placebo. Risk appears to be related to the presence of orthostatic decrease in blood pressure. The risk of blood pressure decreases may be greater in patients taking concomitant medications that induce orthostatic hypotension (such as antihypertensives) or are potent CYP1A2 inhibitors and in patients taking Cymbalta at doses above 60 mg daily. Consideration should be given to dose reduction or discontinuation of Cymbalta in patients who experience symptomatic orthostatic hypotension, falls, and/or syncope during Cymbalta therapy. Risk of falling also appeared to be proportional to a patient's underlying risk for falls and appeared to increase steadily with age. As elderly patients tend to have a higher underlying risk for falls due to a higher prevalence of risk factors such as use of multiple medications, medical comorbidities, and gait disturbances, the impact of increasing age by itself is unclear. Falls with serious consequences including bone fractures and hospitalizations have been reported. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm319241.htm • In a randomized, placebo-controlled study in patients 1 month to less than 4 years of age using an oral formulation of Keppra, a significantly higher risk of increased diastolic blood pressure was observed in the Keppra-treated patients (17%) compared to placebo-treated patients (2%). There was no overall difference in mean diastolic blood pressure between the treatment groups. This disparity between the Keppra and placebo treatment groups was not observed in the studies of older children or in adults. Monitor patients 1 month to less than 4 years of age for increases in diastolic blood pressure. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm413465.htm 
WARNINGS AND PRECAUTIONS Hepatotoxicity
• [Updated study data] In placebo-controlled trials, ALT greater than 3 times the upper limit of normal (ULN) occurred in 61/1,045 (5.8%) and 62/1,002 (6.2%) of patients receiving Aubagio 7 mg and 14 mg, respectively, and 38/997 (3.8%) of patients receiving placebo, during the treatment period. Bone Marrow Effects/Immunosuppression Potential/Infections [updated study data in the following sections]
• White blood cell count decrease • Risk of infection/tuberculosis screening Peripheral Neuropathy • [Updated study data] The incidence of peripheral neuropathy confirmed by nerve conduction studies was 1.4% (13 patients) and 1.9% (17 patients) of patients receiving 7 mg and 14 mg of Aubagio, respectively, compared with 0.4% receiving placebo (4 patients).
Treatment was discontinued in 0.7% (8 patients) with confirmed peripheral neuropathy (3 patients receiving Aubagio 7 mg and 5 patients receiving Aubagio 14 mg). Five of them recovered following treatment discontinuation. Not all cases of peripheral neuropathy resolved with continued treatment. Peripheral neuropathy also occurred in patients receiving leflunomide. Increased Blood Pressure • [Updated study data] In placebo-controlled studies, the mean change from baseline to the end of study in systolic blood pressure was +2.3 mm Hg and +2.7 mm Hg for Aubagio 7 mg and 14 mg, respectively, and -0.6 mm Hg for placebo. The change from baseline in diastolic blood pressure was +1.4 mm Hg and +1.9 mm Hg for Aubagio 7 mg and 14 mg, respectively, and -0.3 mm Hg for placebo. Hypertension was an adverse reaction in 3.1% and 4.3% of patients treated with 7 mg or 14 mg of Aubagio compared with 1.8% for placebo. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm423101.htm 
